Skip to content

Observation on the therapeutic effect of recombinant type XVII collagen lyophilized fibers on skin wound repair after microneedle treatment for androgenetic alopecia

Observation on the therapeutic effect of recombinant type XVII collagen lyophilized fibers on skin wound repair after microneedle treatment for androgenetic alopecia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126136
Enrollment
Unknown
Registered
2026-06-04
Start date
2025-01-24
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic alopecia

Interventions

Minoxidil+MN Control Group:Microneedling combined with topical application of 1 ml minoxidil once every two weeks for a total of 12 weeks
rCOL17+MN Group:Microneedling combined with topical application of 1 ml recombinant type XVII collagen once every two weeks for a total of 12 weeks

Sponsors

Department of Dermatology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 50 years, regardless of gender; 2.Meet the clinical diagnostic criteria for androgenetic alopecia, with hair loss severity classified as Norwood/Hamilton grades III to VI for males and Ludwig grades I to II for females; 3.Patients who commit to not using other treatment methods during the study period; 4.Patients who voluntarily participate, comply with the study requirements, understand the treatment plan and follow-up schedule, and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Women who are pregnant or breastfeeding; 2.Individuals with skin infections, ulcers, or other skin diseases at the site of hair loss that make them unsuitable for treatment; 3.Those who have used medications affecting androgen levels or other topical or systemic drugs that promote hair growth within the 6 months prior to enrollment; 4.Individuals with coagulation disorders; 5.Those with endocrine or metabolic abnormalities, liver or kidney dysfunction, psychiatric disorders, systemic diseases, immune disorders, infectious diseases, etc.; 6.Individuals with hair loss caused by other factors; 7.Those allergic to the study medication.

Design outcomes

Primary

MeasureTime frame
Skin barrier parameters:stratum corneum hydration;Skin barrier parameters:transepidermal water loss;Skin barrier parameters:sebum content level;Wound healing area;Wound healing time;Visual analogue scale score;

Secondary

MeasureTime frame
Adverse reaction;

Countries

China

Contacts

Public ContactCui Fan

Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

45095168@qq.com+86 189 0803 7159

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026